6609 (6609) Fair Value & Analysis

Healthcare · Market cap HK$1.6B

6 6609 6609 · HK

PriceHK$43.32

Fair ValueHK$55.20

Upside+27.4%

Quality72/100

Watch 6609 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$41.40 – HK$69.00

Fair value as of: Jul 2, 2026

From 24 valuation models · updated today

Share price −9.4% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$33.70 – HK$70.50 · fair‑value band HK$41.40 – HK$69.00 · the HK$43.32 price screens below the HK$55.20 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

6609 (6609) currently trades at HK$43.32, while our model-based Fair Value estimate is HK$55.20 — implying the stock looks roughly 27.4% undervalued today. We read business quality at 72/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 6609 generated revenue of HK$408M at a net margin of 20.4%. Revenue grew 49.1% year over year. It earns a return on equity of 7.6%. The balance sheet holds a net cash position of HK$547M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$408M

Revenue growth (YoY) +49.1%

Net margin 20.4%

Return on equity 7.6%

Free cash flow HK$140M FY2025

P/E ratio 17.1

More key figures

Operating margin 10.1%

EPS (TTM) HK$1.32

Net cash HK$547M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

6609 reported revenue of HK$408M in FY2025 versus HK$90.1M in FY2021, a compound +45.9%/yr. Reported net income was HK$83.3M in FY2025.

Revenue +45.9%/yr

FY21 HK$90.1M

FY22 HK$183M

FY23 HK$232M

FY24 HK$278M

FY25 HK$408M

Net income

FY21 −HK$194M

FY22 −HK$200M

FY23 −HK$94.0M

FY24 −HK$13.6M

FY25 HK$83.3M

Is 6609 fairly valued? → Check now

Similar stocks

6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
ABT ABT	1,600 MXN	1,231 MXN	-23%
Abbott Laboratories, ABTT34	R$39.41	R$30.42	-23%
Stryker Corporation S1YK34	R$79.18	R$43.78	-45%
Medtronic plc MDT	$81.67	$60.02	-27%
Boston Scientific Corporation B1SX34	R$229.30	R$43.33	-81%
Edwards Lifesciences Corporation EW	$85.98	$41.02	-52%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 6609 (6609) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$55.20 versus a price of HK$43.32 — about +27% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 6609?

Our model-based fair value for 6609 is HK$55.20 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$43.32.

What is the quality score of 6609?

6609 has a Quality Score of 72/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 6609 (6609)?

6609 reported trailing-twelve-month revenue of about HK$408M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 6609?

The net profit margin of 6609 is about 20.4%, meaning it keeps roughly 20.4% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.